A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

• Status: Terminated
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purposes of this study are:

• to determine the safety and tolerability of multiple doses of A-831 at various doses

• to determine how multiple doses of A-831 are distributed through the bloodstream

• to determine if A-831 reduces the amount of Hepatitis C virus in the blood

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arrow Therapeutics
• Collaborators: David Mutimer, Birmingham; DDS, Dundee; Ed Gane, ACS New Zealand
• Treatments: Antiviral Agents

Criteria

Inclusion Criteria:

• Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical

• Volunteers who have given their written informed consent to participate in the study

• Volunteers who are willing and able to comply with the protocol and study procedures

• Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)

Exclusion Criteria:

• Voulnteers with concurrent medical conditions or taking concurrent medications